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ABSTRACT
Meal-induced insulin secretion is thought to be regulated primarily
by absorbed nutrients and incretin hormones released from the gas-
trointestinal tract. In addition, the parasympathetic nervous system
(PNS) is known to mediate preabsorptive, or cephalic phase, insulin
secretion. Despite evidence that the PNS remains activated during
the absorptive phase of the meal, its role in mediating postprandial
insulin secretion has not been established. To study the role of the
PNS in absorptive phase insulin release, we measured plasma con-
centrations of glucose as well as islet hormones and incretins in six
healthy rhesus monkeys before and for 60 min after meals while they
were infused with saline (control), atropine (muscarinic blockade), or
trimethaphan (nicotinic blockade). During the infusion of saline,
plasma levels of glucose, pancreatic polypeptide (PP), insulin, glucose-
dependent insulinotropic polypeptide, and glucagon-like peptide-1
increased promptly after meal ingestion and remained elevated
throughout the 60 min of the study. The PP response was nearly
abolished in animals treated with trimethaphan, indicating func-
tional blockade of PNS input to the islet, and in contrast to the control
study, there were minimal changes in plasma concentrations of glu-
cose, incretin hormones, and insulin. Because trimethaphan inhibited
glycemic and incretin stimuli in addition to blocking PNS input to the
islet, it was not possible to discern the relative roles of these factors
in the stimulation of insulin secretion. Atropine also significantly
decreased PNS transmission to the islet, as reflected by PP levels
similar to those observed with trimethaphan. Unlike the tri-
methaphan study, plasma glucose levels rose normally during atro-
pine treatment and were similar to those in the control study over the
course of the experiments (114 6 22 and 132 6 23 mmol/Lz60 min,
respectively). In addition, the rise in plasma glucagon-like peptide-1
following the meal was not suppressed by atropine, and the glucose-
dependent insulinotropic polypeptide responses were only modestly
decreased. Despite the significant increases in circulating glucose and
incretins, plasma insulin levels were greatly attenuated by atropine,
so that the 60 min responses were more comparable to those during
trimethaphan treatment than to those in the control study (atropine,
3,576 6 1,284; trimethaphan, 4,128 6 2,616; control, 15,834 6 5,586
pmol/Lz60 min; P , 0.05). Thus, muscarinic blockade markedly sup-
pressed the meal-induced insulin response despite normal postpran-
dial glycemia and significant elevations of incretins. These results
indicate that activation of the PNS during the absorptive phase of
meals contributes significantly to the postprandial insulin secretory
response. (J Clin Endocrinol Metab 86: 1253–1259, 2001)
NORMAL GLUCOSE tolerance requires a rapid insulinsecretory response that is appropriate for the amount
of ingested carbohydrate. In healthy humans, insulin levels
rise soon after food intake, with the major portion of the
b-cell response paralleling the rise in plasma glucose. In
addition, plasma insulin levels increase in direct proportion
to the quantity of carbohydrate ingested (1, 2). This finely
regulated b-cell response is mediated by a system of coor-
dinated inputs to the islet, including stimulation by nutrients
(glucose and certain amino acids), gastrointestinal (GI) hor-
mones, and neural signals, collectively known as the entero-
insular axis (3, 4). Although increases in circulating glucose
are essential for activation of the b-cell, GI hormones released
during nutrient absorption make a substantial contribution
to the normal b-cell response to food ingestion. These GI
hormones, known as incretins, are secreted in proportion to
meal size and increase the responsiveness of the b-cell to
glucose, thus regulating both the magnitude and the rapidity
of normal postprandial insulin release (3, 4). Of the many
candidate GI peptides, only two, glucose-dependent insuli-
notropic polypeptide (GIP) and glucagon-like peptide-1
(GLP-1), are currently considered to be physiologically im-
portant incretins (4–6).
After food intake a small amount of insulin is released
even before there are significant increments in plasma glu-
cose concentrations, a phenomenon termed preabsorptive, or
cephalic phase, insulin secretion (7–9). Even though preab-
sorptive insulin release is a relatively minor component of
total postprandial b-cell secretion, it appears to be physio-
logically important, because studies in both rats and humans
have shown that loss of the preabsorptive insulin response
impairs glucose tolerance (10–13). Preabsorptive insulin se-
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cretion can be prevented by vagotomy or muscarinic block-
ade with atropine (7–9, 13), indicating that it is mediated
primarily by activation of the parasympathetic cholinergic
nerves innervating the islet.
Despite convincing evidence that cholinergic signals stim-
ulate insulin secretion, the contribution of the parasympa-
thetic nervous system (PNS) to meal-induced insulin release
beyond the preabsorptive phase has received little attention.
This is due in great part to methodological difficulties, as
interference with vagal transmission, either surgically or
pharmacologically, frequently produces plasma glucose pro-
files different than those of controls (8). This clouds the
interpretation of PNS effects during the absorptive phase of
insulin secretion when glycemic stimulation has a prominent
role. There is currently no consensus on this issue; PNS
stimulation of meal-induced insulin secretion beyond the
cephalic phase has been suggested by some investigators (14)
and dismissed by others (4), but is typically ignored among
the important mediators of postprandial b-cell secretion (13,
15–17).
In the experiments described below we sought to gain
evidence for a direct role of the PNS to stimulate insulin
secretion during the absorptive phase of meal by measuring
the effects of cholinergic blockade on the glucose, insulin,
and incretin hormone responses to a high carbohydrate,
mixed meal in rhesus monkeys.
Materials and Methods
Animals and catheter implantation
Six adult (aged 11–14 yr) male rhesus monkeys (Macaca mulatta),
weighing 9.1–14.5 kg (mean 6 sem, 11.5 6 0.7 kg), were used for these
studies. Before selection for the study, a physical examination, complete
blood count, and serum biochemistry panel were performed for each
animal. The animals had previously been acclimated to several hours of
chair restraint with a minimum of 10 training sessions (18). At least 1
week before the first experiment, an iliac or femoral artery was cathe-
terized under ketamine/isoflurane anesthesia with a polyurethane cath-
eter connected to a sc vascular access port (Access Technologies, Skokie,
IL) as previously described (18). Animals were housed in the American
Association for Accreditation of Laboratory Animal Care-accredited
facilities of the California Regional Primate Research Center in accor-
dance with standards established by the U.S. Animal Welfare Act and
the Institute of Laboratory Animal Resources. The experimental proto-
cols were approved by the institutional animal use and care committee
at the University of California-Davis and the California Regional Primate
Research Center and were conducted in accordance with the guidelines
of the National Research Council’s Guide for the Care and Use of Lab-
oratory Animals.
Feeding protocol
Each animal was studied three times in randomized order: 1) during
saline infusion, 2) during atropine infusion, and 3) during trimethaphan
infusion. The studies were performed at least 7 days apart. Two animals
had the saline infusion, two animals had the atropine infusion, and two
animals had the trimethaphan infusion as their first experiment. They
were fasted overnight and placed in restraint chairs at least 1 h before
the experiment. A cephalic vein was catheterized for infusion of saline,
atropine, or trimethaphan. Four baseline blood samples (3 mL each)
were drawn from the arterial port at 220, 210, 25, and 0 min. Animals
then ingested a meal consisting of one banana, half of an apple cut into
four pieces, and three monkey chow biscuits (Purina 5047, Ralston
Purina Co., St. Louis, MO). Blood samples were collected 2, 5, 10, 15, 30,
45, and 60 min after the animals began to eat. In each subsequent
experiment, the animals were fed the same amount of food that was
consumed by that animal during the initial experiment. Therefore, the
amount of energy consumed and the macronutrient composition of the
meals did not differ among the treatments. The meals contained an
average of 32.7 6 1.2 g carbohydrate, 6.6 6 2.1 g protein, and 1.7 6 0.4 g
fat and provided approximately 170 Cal (720 joules) energy. Approxi-
mately 76% of the energy in the meals was derived from carbohydrate,
15% from protein, and 9% from fat. The animals were eating for an
average of 24 6 3 min of the 1-h period, and this time period did not
differ among the three experimental conditions.
Pharmacological autonomic blockade
To produce muscarinic blockade and impair activation of cholinergic
receptors during feeding, animals received a primed continuous iv in-
fusion of atropine sulfate (Elkins-Sinn, Cherry Hill, NJ; 0.1 mg/kg bolus
plus 0.001 mg/kgzmin) starting 20 min before the meal and throughout
the experiment. To produce nicotinic blockade of ganglionic neuro-
transmission and abolish all parasympathetic postganglionic signaling
during feeding, trimethaphan camsylate (Arfonad, Roche, Nutley, NJ)
was infused iv (0.1–0.4 mg/min) for 30 min before food ingestion and
throughout the study. Arterial blood pressure was monitored contin-
uously with a digital blood pressure analyzer (DigiMed, Louisville, KY).
The infusion rate of trimethaphan was adjusted to decrease mean arterial
blood pressure (MAP) by more than 20 mm Hg without lowering MAP
below 80 mm Hg. On the average, MAP decreased from 113 6 5 before
trimethaphan infusion to 92 6 3 mm Hg at the time the baseline samples
were drawn (change, 222 6 2 mm Hg).
Assays and data analysis
Blood samples for plasma glucose determination were drawn and
placed in tubes containing heparin. Blood samples for insulin, pancreatic
polypeptide, GIP, and GLP-1 determination were placed in tubes con-
taining ethylenediamine tetraacetate and aprotinin (Sigma, St. Louis,
MO). All samples were kept on ice until centrifugation (20 min at 4 C).
The plasma was decanted and frozen at 220 C until assayed. Plasma
glucose was assayed by the glucose oxidase method with a glucose
analyzer (Beckman Coulter, Inc., Fullerton, CA). Plasma immunoreac-
tive insulin was measured by RIA in unextracted plasma with reagents
supplied by Linco Research, Inc. (St. Louis, MO). The intra- and inter-
assay coefficients of variation for the plasma insulin assay are less than
10% and 14%, respectively. Plasma pancreatic polypeptide (PP), GLP-1,
and GIP were measured by RIA using previously described methods
(19–21).
Calculations and data analysis
Basal values of glucose, PP, insulin, GIP, and GLP-1 were taken as
the mean of the four samples collected before feeding was initiated. The
postprandial responses of glucose and hormones were calculated as
the area under the curve (AUC) above the basal values using the trap-
ezoidal rule. Both the basal values and the responses to feeding (AUC)
were compared among the control, atropine, and trimethaphan studies
using ANOVA and Dunnett’s test to distinguish differences between
groups. In instances where the AUC were different in the control and
either atropine or trimethaphan groups, the percent change was com-
puted for each animal, and means of these percentages were computed
for each group. Within each experimental condition, plasma values were
compared with basal using repeated measures ANOVA with post-hoc
comparisons made using t tests for paired samples. The data are pre-
sented as the mean 6 sem.
Results
Glycemic responses
Arterial plasma glucose responses to the mixed meal in
monkeys treated with saline (control), atropine, or tri-
methaphan are shown in Fig. 1A. Basal (fasting) plasma
glucose levels were unaffected by atropine or trimethaphan
infusion. In the control study, plasma glucose increased sig-
nificantly (;2 mmol/L) above basal levels 10 min after the
start of the meal and remained elevated for the full 60 min
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of observation. Plasma glucose also increased after meal in-
gestion in the atropine-treated group, and the increase was
comparable to that in the control study; all values from 10
min after meal initiation were significantly greater than basal
levels. In contrast, there was a marked diminution, and de-
lay, in the rise of plasma glucose when the monkeys were fed
during the infusion of trimethaphan; values were signifi-
cantly elevated above baseline levels only at 45 and 60 min
after initiation of feeding. The glucose AUC above basal after
feeding for each of the three treatments is shown in Table 1.
The glucose AUCs for the control and atropine studies were
not significantly different from one another, but both were
significantly greater than the glucose AUC in the tri-
methaphan study.
PP
The arterial plasma concentrations of PP during the three
studies are shown in Fig. 1B. Treatment with atropine and
trimethaphan decreased the basal PP concentrations relative
to control levels (35.8 6 4.3 and 39.4 6 3.1, vs. 65.7 6 16
pmol/L, respectively; P , 0.05). In the control study, plasma
TABLE 1. Postprandial responses (AUC) of glucose, pancreatic polypeptide, insulin, GIP, and GLP-1 in monkeys given saline, atropine,
or trimethaphan
Control Atropine Trimethaphan
Glucose (mmol/Lz60 min) 132 6 23 114 6 22 25 6 8a,b
PP (pmol/Lz60 min) 8,507 6 1,872 1,737 6 1,234a 376 6 287a
Insulin (pmol/Lz60 min) 15,834 6 5,586 3,576 6 1,284a 4,128 6 2,616a
GIP (pmol/Lz60 min) 7,464 6 1,879 3,857 6 1,035 2,256 6 1,339a
GLP-1 (pmol/Lz60 min) 318 6 51 357 6 61 144 6 65b
a P , 0.05 vs. control.
b P , 0.05 vs. atropine.
FIG. 1. Plasma concentrations of glucose (A), PP (B), GIP (C), and GLP-1 (D) before, during, and after meals in monkeys infused with saline
(circles/solid line), atropine (squares/dashed line), and trimethaphan (diamonds/dotted line). For A and B, the asterisks denote values different
from basal in the control and atropine groups (P , 0.05). For C and D, the asterisks denote values different from basal in the control group
(P , 0.05), and # denotes values different from basal in both the control and atropine groups.
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PP concentrations increased rapidly after the start of feeding,
peaking at 5-fold basal values at 10 min and declining there-
after for the remainder of the study; all postmeal values were
significantly greater than basal. This rapid increase in PP
during the control study was detectable at the first sample (2
min) after eating commenced and preceded the increase in
plasma glucose levels, which did not rise significantly until
10 min. Compared with the control study, plasma PP did not
increase after the meal in animals pretreated with either
atropine or trimethaphan. As shown in Table 1, atropine and
trimethaphan treatment decreased the 60 min PP response to
feeding by 84 6 9% and 89 6 8%, respectively (P , 0.001 for
both). The PP responses in animals given atropine and those
in animals given trimethaphan were not different from each
other.
Insulin
Figure 2A depicts the arterial plasma insulin values in the
monkeys during the three studies. Treatment with atropine
or trimethaphan did not significantly alter basal insulin lev-
els relative to saline infusion (78 6 15, 95 6 25, and 112 6 22
pmol/L, respectively; Fig. 2A). In the control study, plasma
insulin levels increased significantly within 2 min after the
start of the meal and reached a plateau at 30 min; all values
after initiation of the meal were significantly greater than
baseline levels. The three plasma samples taken in the first
10 min of the meal reflect preabsorptive insulin release, as
glucose levels did not increase significantly until the end of
this period. The preabsorptive insulin response during the
control experiments was 115 6 44 pmol/Lz10 min (Fig. 2B).
As expected, there was no early, preabsorptive, rise in
plasma insulin (8 6 9 pmol/Lz10 min) in the monkeys treated
with atropine (Fig. 2B). However, there was also a notable
effect of atropine on insulin secretion during the absorptive
phase of the meal. In these experiments insulin levels did not
increase significantly until 30 min after meal ingestion, and
the insulin response not only was delayed, but was also
greatly attenuated compared with that in the control study
(Fig. 2A and Table 1). This inhibition of insulin secretion
occurred despite similar increases in plasma glucose in the
control and atropine experiments. When the monkeys were
treated with trimethaphan, the plasma insulin response in
both the cephalic and absorptive phases was also greatly
diminished, with no postprandial time point significantly
higher than basal. However, in these studies glucose levels
did not change from basal in most of the animals, so that
glycemic stimulus of the b-cell was minimal. The overall
postprandial insulin release during muscarinic or nicotinic
blockade was attenuated by 71 6 7% and 80 6 8%, respec-
tively, compared with that in the control study, as shown in
Table 1.
Incretins (GIP and GLP-1)
Plasma concentrations of GIP before and after feeding are
shown in Fig. 1C. Basal GIP concentrations were not changed
by infusion of cholinergic antagonists. After the meal, GIP
concentrations rose in the control and atropine groups to
levels significantly greater than basal by 5 min in the control
and 15 min in the atropine experiments. GIP responses were
variably suppressed in five of the six monkeys during atro-
pine treatment, and for the group as a whole the GIP AUC
was 66% of the control value (Table 1). During the infusion
of trimethaphan the rise in GIP was minimal and did not
achieve statistical significance at any of the postprandial time
points.
Basal concentrations of GLP-1 were not affected by para-
sympathetic blockade with either atropine or trimethaphan
(Fig. 1D). Meal ingestion caused plasma GLP-1 levels to rise
significantly compared with baseline in both the control and
atropine-treated animals, and the AUCs were similar during
these two experiments (Table 1). In contrast, when the mon-
keys were treated with trimethaphan, plasma GLP-1 levels
did not increase significantly after food ingestion compared
with baseline. The mean AUC for GLP-1 during the control
and atropine studies were greater than twice the calculated
response during trimethaphan treatment.
Discussion
In this study we sought to determine the effect of cholin-
ergic input to the pancreatic islets on the insulin response
FIG. 2. A, Plasma concentrations of insulin before, during, and after
meals in monkeys infused with saline (circles/solid line), atropine
(squares/dashed line), and trimethaphan (diamonds/dotted line).
The asterisks denote values different from basal in the control group
(P , 0.05). B, Cephalic phase insulin secretion in monkeys treated
with saline, atropine, and trimethaphan. The vertical bars represent
the AUC above basal insulin for the first 10 min after the meal.
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during the absorptive phase of a meal. To this end we
blocked cholinergic-muscarinic (atropine) or nicotinic gan-
glionic (trimethaphan) signaling before and for 60 min after
the consumption of a high carbohydrate meal and compared
the insulin responses to a control study. Plasma levels of
glucose and the incretin hormones GIP and GLP-1 were also
measured to allow estimates of the degree of b-cell stimu-
lation by these three factors in each of the experimental
conditions. The major finding of this study is that muscarinic
blockade markedly attenuated the insulin response for the
first hour after meal ingestion despite the presence of normal
elevations of plasma glucose and GLP-1 and a GIP response
that was only modestly reduced. This observation suggests
that muscarinic signaling to the islet is essential for the in-
sulin response to the absorptive phase of a meal. If so, the role
of the PNS extends beyond its currently accepted function of
mediating preabsorptive, or cephalic phase, insulin secre-
tion. This finding indicates that the traditional view that
nutrient substrates and GI hormones are the sole mediators
of the sustained insulin response during nutrient absorption
should be systematically and rigorously reexamined.
The traditional view of meal-induced insulin secretion has
been that once nutrient absorption has commenced stimu-
lation of the b-cell is mediated predominantly by circulating
glucose and the incretin hormones, and therefore, that the
PNS does not contribute significantly to insulin secretion
during this period (4, 13, 15–17). This view has persisted
despite direct evidence that activation of the PNS input to the
islet can markedly stimulate insulin release (22) and indirect
evidence that the PNS remains activated during the absorp-
tive phase of the meal (23–25). Part of the problem has been
the difficulty in separating direct effects of PNS blockade on
the islet from indirect effects due to alterations in GI function
and consequently blood glucose. Therefore, studies using
surgical or pharmacological methods of denervating the
b-cell have also reduced (8) or accelerated (26, 27) gastric
emptying and thereby either reduced or accelerated the post-
prandial glycemic excursions. Because of the variability in-
troduced in the glucose stimulus to the islet, it has not been
possible to determine the direct contribution of PNS activa-
tion to meal-induced insulin secretion in these studies. For
this reason it is widely believed that the major role of the PNS
in insulin secretion during meal absorption is indirect, via the
regulation of gastric emptying and control of the rate of
delivery of nutrients to the intestine. The alternative view,
that there are important effects of the PNS to directly stim-
ulate insulin secretion during meal absorption, requires ex-
perimental conditions in which PNS blockade has little effect
on plasma glucose. Fortunately, in the present study post-
prandial glucose levels during atropine infusion were similar
to those in the control experiments despite clear muscarinic
blockade, as indicated by the near-total inhibition of PP se-
cretion. As the insulin response to the meal was also mark-
edly impaired by atropine, this study demonstrates an un-
ambiguous effect of cholinergic signaling to stimulate insulin
secretion during the absorptive phase of a meal.
Our findings are supported by the results of two previous
studies in other animal models, both of which bypassed the
stomach by infusing nutrients directly into the duodenum.
Schusdziarra and colleagues showed that atropine signifi-
cantly inhibited insulin secretion during 40 min of enteral
nutrient infusion to anesthetized rats (28). Greenberg and
Pokol-Daniel showed that cryogenic blockade of vagal neu-
rotransmission during intraduodenal perfusion of mixed nu-
trients or glucose caused an approximately 50% decrease in
the insulin response in the dog (29). In each of these studies,
as in our study, the meal-induced glucose levels were not
appreciably different between control conditions and those
of PNS inactivation, ruling out a diminished glycemic stim-
ulus as the cause of the subnormal insulin release. Taken
together, these data support an essential role for the PNS in
the composite signal that triggers insulin secretion during the
absorptive phase of meals.
Although it is clear that the elevation in plasma glucose
that occurs after meals is critical for a normal b-cell response,
incretin hormones also play an important role in this process.
The incretin effect, defined as the augmentation of insulin
secretion seen when glucose is administered orally vs. iv, has
been attributed primarily to the actions of GLP-1 and GIP,
and accounts for as much as 50–70% of postprandial insulin
secretion (2, 4). In the present study we have measured the
two best-established incretin hormones and can therefore
assess their potential to contribute to meal-induced insulin
secretion. For example, plasma levels of GLP-1 were not
substantially altered by atropine treatment, indicating that
muscarinic pathways contribute little to meal-induced GLP-1
release in monkeys. Therefore, diminished stimulation by
GLP-1 cannot account for the attenuated insulin response
observed during the atropine studies. However, GIP levels
were inhibited by one third during atropine treatment, rais-
ing the possibility that lower levels of this incretin contrib-
uted to the decreased insulin response in these experiments.
Previous studies in rats in which GIP action was blocked
either by immunoneutralization of circulating GIP or with
GIP receptor antagonists have shown an approximately 40%
reduction in the insulin response (30, 31). A similar decre-
ment in insulin secretion in the 60 min after an oral glucose
load was recently reported in mice with a targeted deletion
of the GIP receptor gene (32). In contrast, insulin secretion
was decreased by 70% in the atropine studies even though
the majority of the GIP response was preserved. Thus, al-
though it is possible that the lower GIP levels during atropine
administration explain a portion of the decrement in post-
prandial insulin release, it is unlikely that impaired incretin
stimulation can fully account for the large attenuation of the
insulin response that we observed.
Although muscarinic blockade had only limited effects on
the secretion of GI hormones, it is likely that atropine delayed
gastric emptying to some extent in the present study. Indeed,
because of the importance of vagal innervation in the control
of gastric motility, blockade of either muscarinic or nicotinic
signaling is expected to retard gastric emptying and there-
fore the delivery of nutrients to the absorptive surface of the
small intestine. This, in turn, delays glucose absorption and
the stimulation of GI hormone release. For example, we infer
from the minimal meal-induced increments of plasma glu-
cose and incretin levels during trimethaphan that gastric
emptying was severely impaired during the 60 min of this
experiment. We anticipated that muscarinic blockade would
have at least a modest effect on gastric emptying based on
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previously published studies (8, 33). Although we did not
directly measure gastric emptying in the present study, we
infer that atropine slowed the gastric delivery of nutrients
based on the postprandial GIP profile. Secretion of GIP from
upper intestinal K cells is tightly coupled to glucose absorp-
tion by the gut mucosa (34, 35), and studies in both humans
and animals indicate that atropine does not directly block the
release of GIP (29, 36). Therefore the modest reduction in the
GIP profiles observed in atropine-treated monkeys probably
reflects a modest reduction of glucose delivery to the upper
small intestine.
Given the probability that gastric emptying of the meal
was modestly delayed by atropine treatment, with decreased
rates of glucose absorption, the equivalent plasma glucose
excursions in the atropine experiments compared with con-
trols must be explained by other factors. The monkeys were
fed meals that were very low in fat, so that the potent effect
of ingested lipid to inhibit gastric emptying and add to the
action of atropine was minimal. In addition, the 25-min pe-
riod of meal intake probably mitigated the effects of atropine
on gastric motility to some degree. Moran and colleagues
have shown that gastric emptying in monkeys is more rapid
while intake is ongoing and decreases once feeding has
ceased and the stomach is full (37). In our experiments the
consumption of the meal over 25 min probably permitted
greater rates of gastric emptying than would have occurred
if the animals had been given a bolus of food over a shorter
time span. Finally, it seems likely that decreased intestinal
glucose uptake during atropine was counterbalanced by di-
minished glucose clearance, resulting in a postmeal glucose
profile similar to the control condition. As insulin-stimulated
glucose disposal and suppression of hepatic glucose output
are essential for normal postprandial glycemia, the lower
insulin response in the atropine-treated monkeys probably
caused a higher glucose excursion than would have other-
wise been seen for the degree of glucose absorption. What-
ever the mechanism, the similar plasma glucose profiles in
the atropine and control groups coupled with the markedly
decreased plasma insulin levels in the atropine-treated group
rule out insufficient stimulation by glucose as the cause of the
atropine-induced impairment of meal-induced insulin secre-
tion. Furthermore, as the meal given to the monkeys in this
study was 80% carbohydrate, it is unlikely that differences in
postprandial levels of amino acids or lipids during the con-
trol and atropine experiments are responsible for the de-
creased insulin responses during muscarinic blockade.
In the present study cholinergic blockade did not have a
significant effect on fasting insulin levels. We infer from these
data that parasympathetic input to the islet does not have a
major effect on basal insulin secretion in the fasting state. This
inference is consistent with previous studies showing that
humans given atropine (38–40) and rats with surgical va-
gotomies (7) had minimal changes in fasting plasma insulin
values. In fact, as it has been shown that atropine does not
change the insulin levels in healthy humans receiving iv
glucose (36), it appears that PNS stimulation of insulin se-
cretion occurs only when nutrients are ingested. In this re-
gard it is worth considering that the incretin effect, which is
calculated as the difference in insulin or C peptide levels
stimulated by oral glucose vs. an equal glycemic stimulus
from iv glucose (2), may include more than just the effects of
insulinotropic GI hormones. As cholinergic, muscarinic sig-
naling is activated by glucose ingestion, but not by glucose
infusion, neural signals to the islet may contribute to the
generally applied calculation of the incretin effect.
In summary, we have found that muscarinic-cholinergic
blockade with atropine inhibited meal-induced insulin se-
cretion in rhesus monkeys. As atropine did not have major
effects on the glycemic and incretin stimulation of the b-cell,
this finding suggests a direct role of the PNS to mediate the
absorptive phase insulin response. These results suggest that
neural regulation of postprandial insulin secretion is more
important than has been previously believed and emphasize
that disrupting islet innervation may reduce the insulin re-
sponse to meals.
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